UQ in-vitro Genome Engineering and Disease Modelling Service (IGEDMS)

The UQ in-vitro Genome Engineering and Disease Modelling Service (IGEDMS) is located at the Australian Institute for Bioengineering and Nanotechnology (AIBN). As a service node for Phenomic Australia, IGEDMS offers bespoke solutions for researchers and industry to assist in the tailoring and optimisation of cell culture format using pluripotent stem cells.

The service enables Australian researchers and the biopharmaceutical industry to use pluripotent stem cells to study and test the impact of genetic mutations on disease. The service's adaptable and scalable disease-modelling platform will also enable improved drug screening capabilities. 

Order form

If you would like to order from the in-vitro Genome Engineering and Disease Modelling Service (IGEDMS), please send your details through via the form below.

Order form

Contact us

Get in touch to learn more about our research.

Professor Ernst Wolvetang

Senior Group Leader, AIBN
QLD Node Leader, TANCR-Phenomics Australia NNAT Initiative


Dr Madiha (Maddy) Yunus

Postdoctoral Research Fellow, in-vitro Genome Engineering and Disease Modelling Service


The in-vitro Genome Engineering and Disease Modelling Service (IGEDMS) provides a broad panel of in-vivo and in-vitro genome engineering and disease modelling, functional genomics and high-throughput screening, biobanking and pathology services and technical expertise, for discovery and a new understanding of the molecular basis of disease to benefit all Australians.


iPSC Reprogramming

As a service node for Phenomics Australia, we provide on-demand reprogramming of patient samples into iPSCs. We can reprogram iPSCs from various primary cell types and support expansion of large-scale iPSC cohort. Our iPSC reprogramming service includes:

  • Consultation and delivery of reprogramming factors via Sendai
  • Reprogramming of iPSCs derivation from blood cells, fibroblasts and PBMCs
  • Feeder-free maintenance and expansion of iPSCs
  • Quality control check by confirmation of virus clearance
  • Confirmation of iPSC morphology via immunofluorescence for pluripotency markers
  • Confirmation of genomic integrity via karyotyping.

We can also offer differentiation services into the lineage of your interest.

CRISPR mutagenesis

Working together with Phenomics Australia, we offer comprehensive services in cellular gene editing using CRISPR and stem cell modification. Using CRISPR technology, we can generate knock-in, knock-out, point-mutated, corrected and reporter cell lines for the genes of your interest. Our CRISPR service includes:

  • Consultation, generation and validation of required plasmid(s)
  • Electroporation of plasmid(s) into nominated cell line of choice
  • PCR screening and Sanger sequencing to identify the modified clones
  • Karyotype to assess genomic integrity
  • Cryopreservation (3 vials per line, up to 3 clones).


We provide on-demand organoid production across a broad range of human disease, drug responses, genome engineering, biobanking, phenotyping and screening. Our services include:

  • High-throughput multi-tissue organoid production
  • Organoid model, optimisation, and upscaling services
  • High-throughput functional/drug screening
  • High content imaging and analysis
  • Collaborative development of new and innovative organoid models.

Other Services

High-throughput screening and imaging

Using our state-of-the-art facility, we can provide high-throughput screening and imaging services to aid disease cell-model development and characterise therapeutic compounds.

Training, consultation, and technical support

We offer consultation, guidance, training, technical and grant writing support for the establishment of relevant iPSC technologies that suit the needs of the end users.

Blood processing and cryopreservation

We can isolate peripheral blood mononuclear cells (PBMCS) from whole blood as per your requirements.

The in-vitro Genome Engineering and Disease Modelling Service (IGEDMS) acknowledges Australia’s Traditional Owners and pays respect to the past and present Elders of the nation’s Aboriginal and Torres Strait Islander communities. We honour and celebrate the spiritual, cultural, and customary connections of Traditional Owners to the country and the biodiversity that forms part of that country.
The in-vitro Genome Engineering and Disease Modelling Service (IGEDMS) is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy, NCRIS. NCRIS supports Australia’s research capability by investing in research infrastructure and making it accessible to researchers across the nation.